Biotech in the Bay Area is professionalizing, and one of the most important investments companies are making right now is in their chain-of-custody logistics: the systems, training, and monitoring that protect a shipment from the moment it leaves a lab to the moment it arrives somewhere else. According to the IQVIA Institute for Human Data Science, cold chain issues cost the pharmaceutical industry as much as $35 billion a year in losses. For an early-stage company, that risk isn’t abstract. It’s the difference between a funding round moving forward and a setback nobody budgeted for.
What does chain-of-custody infrastructure actually mean for a biotech company?
Chain-of-custody infrastructure is the combination of trained personnel, continuous monitoring, documented handoffs, and accountable tracking that protects a shipment at every point between origin and destination. For a biotech company, that typically means temperature-monitored transport, HIPAA-trained couriers, GPS-tracked custody records, and a documented account of exactly who handled a shipment and when.
None of that is exciting to talk about. That’s exactly why it gets deferred at growing companies watching every dollar. But the moment something goes wrong, the absence of that infrastructure becomes the most expensive line item in the budget, not the smallest.
What happens when chain-of-custody infrastructure fails?
When chain-of-custody infrastructure fails, the damage is rarely limited to a single shipment or a single sample. In 2020, a contractor at Rensselaer Polytechnic Institute shut off a laboratory freezer to silence an alarm, and the resulting temperature rise destroyed cell cultures and research samples that had been maintained for more than 20 years. RPI’s lawsuit against the cleaning contractor sought more than $1 million just to attempt recreating the lost work, and some of it may never be recreated at all.
The lesson here isn’t about any one person. It’s about what happens when critical materials rely on infrastructure that was never built with enough redundancy, training, or alarm-response protocol to catch a failure before it became permanent. Biotech companies face the same exposure any time samples, prototypes, or research materials move without a system built to protect them.
Why do liability caps make general couriers a risk for irreplaceable materials?
General couriers are built to move parcels, and their liability terms reflect that. In Hampton v. Federal Express Corp., a hospital shipped blood samples needed to match a bone marrow donor for a 13-year-old cancer patient. The package was lost in transit, the transplant was cancelled, and the family’s claim, valued at more than $3 million, was capped at $100 under the carrier’s standard released-value liability limit.
That case is decades old, but the underlying terms haven’t changed much. A liability cap built for a lost package of merchandise was never designed to reflect the value of a biological sample, a clinical trial batch, or months of research that can’t be replaced on a Tuesday afternoon. For biotech companies, the real cost of a logistics failure has almost nothing to do with what a courier’s contract says it owes.
Chain-of-Custody Infrastructure vs. General Courier Services
| Capability | Chain-of-Custody Infrastructure | General Courier Service |
| Temperature monitoring | Continuous monitoring built into every shipment | Rarely standard; often an add-on if available at all |
| Handler training | HIPAA-trained drivers, dedicated to sensitive materials | General delivery training, not materials-specific |
| Liability terms | Structured around the actual value of what’s shipped | Standard released-value caps, often far below actual value |
| Documentation | Full chain-of-custody record for every handoff | Basic delivery confirmation only |
| Accountability | Dedicated, trained personnel accountable for custody | Variable, often contracted or subcontracted labor |
How should an early-stage biotech budget for logistics infrastructure?
Budget for chain-of-custody infrastructure the way you’d budget for lab equipment, not the way you’d budget for a nice-to-have. A dedicated logistics partner is a fixed, predictable line item. A lost shipment or a broken chain of custody almost never is, and the bill for that one shows up as a delayed trial, a damaged partnership, or months of work you can’t get back.
You don’t need to overspend on this to get it right, but you also can’t treat it as the easiest place to cut. What actually matters is starting the budget conversation from the materials you can’t afford to lose, not from whatever line item looks easiest to trim. A single funding round, submission, or partnership can hinge on one shipment arriving intact and verifiable. That’s a hard thing to put a price tag on until it’s gone.
The Bottom Line
Biotech in the Bay Area is professionalizing, and the companies growing fastest are the ones treating chain-of-custody infrastructure as core to how they operate, not as something to defer until later. The cases above didn’t happen to companies that were careless. They happened because the systems protecting critical materials weren’t built to the standard the materials themselves required.
UltraEx works with growing biotech companies across Northern California to build that standard in from the start, with HIPAA-trained drivers, continuous monitoring, and full chain-of-custody documentation on every shipment. If your company is scaling and your logistics haven’t scaled with it, that’s worth a conversation before it becomes a much more expensive one.
